Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 6/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | PLAU | P00749 | 2/20 | 0.32 |
| ▸ | GPR6 | P46095 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1684576 | 0.90 | CCR8 (0.36) | CCR8KCNH2NAMPTPLAUGPR6 | |
| SCHEMBL12238997 | 0.89 | L3MBTL1 (0.42) | CCR8KCNH2NAMPTCYP2C9HSD17B10 | |
| SCHEMBL12239014 | 0.88 | CYP3A4 (0.40) | USP2CYP2C9HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL12238859 | 0.85 | PLAU (0.32) | PLAU | |
| SCHEMBL12239015 | 0.85 | NAMPT (0.34) | NAMPTPLAU | |
| SCHEMBL12238775 | 0.85 | VNN1 (0.35) | PLAU | |
| SCHEMBL12239007 | 0.84 | CRBN (0.38) | USP2CYP2C9CYP1A2CYP3A4 | |
| SCHEMBL12302393 | 0.83 | ACACB (0.33) | KCNH2PLAUCYP2C9HSD17B10CYP1A2 | |
| SCHEMBL12239806 | 0.82 | CHRM2 (0.41) | NAMPTCYP2C9CYP3A4 | |
| SCHEMBL12238774 | 0.82 | NAMPT (0.34) | NAMPTPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039472-B2 | Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20110237572-A1 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2011-09-29 | — | — | US | disclosed |
| US-20100130506-A1 | Organic Compounds | NOVARTIS AG | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237572-A1 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | SCNN1B, SCNN1A, SCNN1G | CCR8 3041/4885KCNH2 20/4885NAMPT 3224/4885 |
| US-20100130506-A1 | Organic Compounds | OR10J3, REN, CACNA1E | CCR8 1001/4885KCNH2 31/4885NAMPT 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.